Patents by Inventor Wataru Kawahata

Wataru Kawahata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230365589
    Abstract: The present invention provides an amine derivative having a DYRK-inhibiting activity and represented by formula (1): wherein A1, A2, L1, L2, X, Z, R1 and R4 are as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 16, 2023
    Applicants: Sumitomo Pharma Co., Ltd., CARNA BIOSCIENCES, INC.
    Inventors: Shingo TOJO, Daisuke URABE, Hitoshi WATANABE, Wataru KAWAHATA, Hideki MORIYAMA, Yuko ASAMITSU
  • Publication number: 20230138851
    Abstract: The present invention provides a compound that has an inhibitory effect on DYRK and that is represented by general formula (I): wherein Q, R1, R2 and R3 are as defined in the description.
    Type: Application
    Filed: January 28, 2021
    Publication date: May 4, 2023
    Applicant: CARNA BIOSCIENCES, INC.
    Inventors: Ayako SAWA, Wataru KAWAHATA, Yuko ASAMITSU, Masaaki SAWA, Yasuhiro IWATA, Hideki MORIYAMA, Shingo TOJO, Daisuke URABE
  • Patent number: 10793575
    Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: October 6, 2020
    Assignee: CARNA BIOSCIENCES, INC.
    Inventors: Wataru Kawahata, Takao Kiyoi, Takayuki Irie, Tokiko Asami, Masaaki Sawa, Shigeki Kashimoto
  • Publication number: 20190359616
    Abstract: The present invention provides with an oxoisoquinoline derivative represented by the formula (I) (in the formula, Q and R1 are as defined in the description) or a pharmaceutically acceptable salt thereof, which is useful as a Bruton's kinase inhibitor for treating cancer, B-cell lymphoma, chronic lymphocytic leukemia and the like.
    Type: Application
    Filed: November 24, 2017
    Publication date: November 28, 2019
    Applicant: CARNA BIOSCIENCES, INC.
    Inventors: Wataru KAWAHATA, Takao KIYOI, Takayuki IRIE, Tokiko ASAMI, Masaaki SAWA, Shigeki KASHIMOTO
  • Patent number: 9656995
    Abstract: The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, R2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C—R3, R3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: May 23, 2017
    Assignee: CARNA BIOSCIENCES, INC.
    Inventors: Wataru Kawahata, Tokiko Asami, Masaaki Sawa, Yuko Asamitsu, Takayuki Irie, Takahiro Miyake, Takao Kiyoi
  • Publication number: 20160221991
    Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, either of Z1 and Z2 represents carbon atom and the other is nitrogen atom, or both of the Z1 and Z2 represent nitrogen atoms, Q is selected from a structure (a) and (b) described below: wherein R2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, R3 represents a hydrogen atom or a halogen atom, Y represents a nitrogen atom or a carbon atom, and the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 12, 2014
    Publication date: August 4, 2016
    Inventors: Takahiro MIYAKE, Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA
  • Publication number: 20160207906
    Abstract: To provide a novel 2,6-diaminopyrimidine derivative by the following formula (I): A 2,6-diaminopyrimidine derivative is represented by the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, Z1 and Z2 represent carbon atoms, or either 1 or 2 of the Z1 and Z2 represent nitrogen atoms, Q is selected from a structure (a) or (b) described below: R2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, R3 represents a hydrogen atom or a halogen atom, Y represents a nitrogen atom or a carbon atom, and the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond.
    Type: Application
    Filed: September 1, 2014
    Publication date: July 21, 2016
    Inventors: Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA, Takayuki IRIE
  • Publication number: 20160168122
    Abstract: The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, R2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C—R3, R3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 15, 2014
    Publication date: June 16, 2016
    Inventors: Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA, Yuko ASAMITSU, Takayuki IRIE, Takahiro MIYAKE, Takao KIYOI
  • Publication number: 20150011751
    Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R1 and R5 may be combined to form a saturated or unsaturate
    Type: Application
    Filed: March 7, 2013
    Publication date: January 8, 2015
    Inventors: Wataru Kawahata, Tokiko Asami, Masaaki Sawa, Yuko Asamitsu, Takayuki Irie, Takahiro Miyake, Takao Kiyoi